摘要
胰腺癌早期检测是决定这一致命疾病的预后和治疗的长期挑战。虽然胰腺癌发病率低(占所有恶性肿瘤2%),但它是美国第四大癌症死因,其死亡率大于85%,因为疾病发展早期难以诊断。用于筛选病情恶化前患者的诊断工具的相对缺乏是其高死亡率的主要因素。事实上,80-90%的胰腺癌患者在诊断时有较小的不可切除肿瘤。因此,用于检测早期胰腺癌的高灵敏度诊断成像模式是急需的,这将挽救数以万计的患者。许多关于胰腺癌各方面的综述已发表,包括生物学、筛选和治疗,但关于早期检测的信息很少,尤其是高灵敏度模式,如正电子发射断层显像(PET)。现在与CT结合的[18F]FDG成像(PET/CT)对于可切除和治愈的胰腺癌小病灶(约2-3 mm)的检测缺乏必要的灵敏度和特异性。此外,[18F]FDG在炎症组织中的积累是大问题。因此,对肿瘤兼备高灵敏度和高选择性的PET示踪物是早期胰腺癌PET成像必需的。本文着重讲述了用PET对胰腺癌的早期检测,包括新靶点和新PET示踪物的开发和应用。
关键词: [18F]乳糖,HIP/PAP,分子成像,PDAC,PET。
Current Medicinal Chemistry
Title:Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Volume: 22 Issue: 29
Author(s): Mian M. Alauddin and Louis De Palatis
Affiliation:
关键词: [18F]乳糖,HIP/PAP,分子成像,PDAC,PET。
摘要: Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to cancer in the U.S. A major cause for the high mortality rate, which exceeds 85%, is the difficulty in diagnosing the disease early in its development. The relative lack of reliable diagnostic tools to screen patients who are asymptomatic prior to the aggressive progression of disease has been the primary contributing factor in the high mortality rate in this patient population. Indeed, 80-90% of patients with pancreatic cancer have relatively small unresectable tumors at the time of diagnosis. Therefore, there is an unmet need for a highly sensitive diagnostic imaging modality to detect early-stage pancreatic cancer, as this may save the lives of many thousands of patients. Many literature reviews have been published on various aspects of pancreatic cancer, including biology, screening, and therapy; however, limited information is available on early detection, especially the use of highly sensitive modalities such as positron emission tomography (PET). Current [18F]FDG/PET imaging combined with CT (PET/CT) lacks the necessary sensitivity and specificity for detection of small lesions (~2-3 mm) of pancreatic cancer that may be resectable and curable. Furthermore, accumulation of [18F]FDG in inflammatory tissue is a major problem; therefore, an appropriate PET tracer that is both highly sensitive and specific for carcinoma is necessary for PET imaging of early stage pancreatic cancer. This review focuses on early detection of pancreatic cancer by PET, including new targets and the development and application of new PET tracers.
Export Options
About this article
Cite this article as:
Mian M. Alauddin and Louis De Palatis , Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes, Current Medicinal Chemistry 2015; 22 (29) . https://dx.doi.org/10.2174/0929867322666150821094015
DOI https://dx.doi.org/10.2174/0929867322666150821094015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Editorial [Hot Topic: Recent Advances Into the Molecular Mechanisms and Therapeutic Targeting of Hepatocellular Carcinoma (Guest Editors: Dr. Mei-Sze Chua and Li Wang)]
Anti-Cancer Agents in Medicinal Chemistry Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Chemoprotective Effects of Propolis on Aflatoxin B1-Induced Hepatotoxicity in Rats: Oxidative Damage and Hepatotoxicity by Modulating TP53, Oxidative Stress
Current Proteomics Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Fasciola Hepatica Extract Induces Cell Death of Mammalian Cells
Anti-Infective Agents Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry New Chalcones Containing 5-Fluorouracil Exhibiting in vitro Anti-Cancer Activity
Letters in Organic Chemistry Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options
Current Cancer Drug Targets The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets